RxDoctor Payments Data

Ryan Whitney, MD

Cardiovascular Disease · Braselton, GANPI 1811004088

Payments from drug & device makers

What this record shows

18 manufacturers reported payments, led by GE HealthCare at 52.7% of the total. Reporting peaked in 2020 at $2,938 and has fallen 94.2% since, to $170 in 2025.

$4,799in general payments, 2019–2025

Across 122 payments — averaging $39.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GE HealthCare$3K
  • Pfizer$429
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$398
  • Amgen$314
  • Terumo Medical Corporation$264
  • Johnson & Johnson$221
  • plus $646 from 12 others
$46,935in research payments, 2019–2025

Across 4 payments — averaging $11,734 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$46K
  • Abbott$550

What the payments were for

  • Consulting fees$2,52753%
  • Food & beverage$2,27247%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,799 in reported general payments places this provider in the 65th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$299,818
Medicare patients
2,566
Services billed
7,427

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban785$938,938
XareltoRivaroxaban292$360,469
EntrestoSacubitril/Valsartan225$254,843
Repatha SureclickEvolocumab233$242,870
FarxigaDapagliflozin Propanediol70$75,875
Praluent PenAlirocumab59$46,905
JardianceEmpagliflozin36$46,077
Repatha SyringeEvolocumab20$20,791
BrilintaTicagrelor24$18,990
NexlizetBempedoic Acid/Ezetimibe14$15,795
Metoprolol Succinate883$11,036
Rosuvastatin Calcium872$9,565
Atorvastatin Calcium987$8,926
Flecainide Acetate99$6,878
Ezetimibe309$6,131

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$429$938,938785 claims
Johnson & JohnsonXarelto$221$360,469292 claims
NovartisEntresto$56$254,843225 claims
AstraZenecaFarxiga, Brilinta$85$94,86594 claims
Boehringer IngelheimJardiance$55$46,07736 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Braselton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →